ctDNA, or circulating tumor DNA, are small fragments of DNA that are released into the blood stream from tumor cells in the body. ctDNA can be isolated from blood samples, known as liquid biopsies, and the ctDNA can be analyzed via DNA sequencing in order to identify the specific mutations that are driving disease progression.
It has been shown that ctDNA samples can be analyzed to identify emerging cancer recurrence, drug-resistant mutations, and secondary metastasis. Oncologists can use liquid biopsy tests in order to make changes to a patient’s therapeutic regimen, and better fight the disease.
The ideal ctDNA assay needs to be focused enough to provide high sensitivity to known mutations, but broad enough to identify novel changes in the ctDNA genetic signature.
Nova BioLabs uses next-generation sequencing (NGS) in conjunction with advanced bioinformatics in order to identify very small amounts of ctDNA from liquid biopsies. Our approach is to create a personalized liquid biopsy test that allows for more sensitive detection of ctDNA mutations, identifying residual disease and emerging resistance mutations that may not be detected with conventional testing technologies.